Solute Carrier Family 35 Member F2 Regulates Cisplatin Resistance and Promotes Malignant Progression of Pancreatic Cancer by Regulating RNA Binding Motif Protein 14

Shuxian Zhang, Qingqing Li, Huixiao Yuan, Ling Ren, Xuyang Liang, Shouying Li, Shengxiang Lv, and Hua Jiang

1Department of Gastroenterology, Lianyungang Clinical College of Nanjing Medical University, Nanjing, Jiangsu, China
2Department of Geriatrics, Shanghai Oriental Clinical Medical School of Nanjing Medical University, Shanghai, China
3Department of Geriatrics, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China

Correspondence should be addressed to Shengxiang Lv; lvshengxiang2009@126.com and Hua Jiang; huajiang2013@tongji.edu.cn

Received 21 March 2022; Revised 26 April 2022; Accepted 5 May 2022; Published 27 May 2022

Academic Editor: Alamgeer Yuchi

Copyright © 2022 Shuxian Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

We aimed to explore the role of Solute Carrier Family 35 Member F2 (SLC35F2) in pancreatic cancer (PCa) and to further study whether SLC35F2 regulates cisplatin resistance of PCa cells through the modulation of RNA binding motif protein 14 (RBM14) expression. SLC35F2 expression in 60 pairs of PCa tissues and adjacent ones was studied by RT-PCR analysis. Meanwhile, SLC35F2 expression levels in PCa cell lines were also evaluated by qPCR assay. In addition, SLC35F2 knockdown models were constructed in PCa cisplatin-resistant cells. Furthermore, we determined the interaction between SLC35F2 and RBM14 via luciferase assay. The findings of the present study demonstrated that SLC35F2 was significantly upregulated in PCa tissues. High level of SLC35F2 indicated higher incidence of metastasis and shorter survival rates. In vitro cell experiments revealed that knockdown of SLC35F2 suppressed cell invasion and metastasis capacity of cisplatin-resistant PCa cell lines PANC-1/DDP and CFPAC-1/DDP. It was also suggested that the key protein RBM14 in the SLC35F2 knockdown group was remarkably reduced. SLC35F2 can bind to RBM14 specifically. Overexpression of RBM14 partially reversed the effects of knockdown of SLC35F2 on the development of PCa. SLC35F2 expression in PCa tissues and cell lines is remarkably increased. In addition, it was also suggested that SLC35F2 may regulate cisplatin resistance of PCa cells through modulating RBM14 expression. In conclusion, it is conceivable from the study that SLC35F2 was remarkably upregulated in PCa and promoted the malignancy of PCa via regulating RBM14.

1. Introduction

According to the latest epidemiological statistics released by the American Cancer Society, there were an estimated 43,090 PCa-related deaths, including 22,300 in men and 20,790 in women. Meanwhile, this cancer has been the fourth leading cause of cancer-related death in men, accounting for 7% of all cancer deaths, second to lung and bronchial cancer (27%), colorectal cancer (9%), and prostate cancer (8%). Among female tumor-related cases, PCa accounts for 7% of deaths, also ranking fourth, after lung and bronchial cancer (25%), breast cancer (14%), and colorectal cancer (8%) [1–4]. However, for the early symptoms of PCa are not obvious, this disease was often found in advanced stage, leading to a very low five-year survival rate. At the time of diagnosis, less than 5% of tumor patients could be surgically removed [5–7].

Cisplatin is a first-generation platinum drug and a nonspecific cell cycle drug [8, 9]. The main targets of cisplatin are nucleophilic DNA, proteins, and RNA in cells [9, 10]. Currently, cisplatin is a broad-spectrum anticancer drug in the clinical treatment of tumors [10, 11]. However, patients often show some resistance in the treatment process, and the specific reasons still remain unclear [12]. One of
the most important mechanisms of cisplatin resistance is the enhancement of DNA repair function and the cancellation of cisplatin’s inhibitory effect on DNA repair [13, 14]. Effective DNA damage repair depends in part on structurally specific nuclease family members removing damaged groups or nucleotides and various intermediate DNA structures [14]. The SLC35F2 gene is located in the long arm of human chromosome 11, which is closely adjacent to it (11q22.3) by RAB39, a member of the Ras family of oncoproteins [15]. In addition, SLC35F2 plays a key role in DNA replication and repair [16]. Therefore, this study intends to observe the effects of downregulation of SLC35F2 on the sensitivity to chemotherapy in PCa in vivo and in vitro, so as to lay a theoretical foundation for the clinical enhancement of the chemotherapy sensitivity of PCa and other malignant tumors.

2. Materials and Methods

2.1. PCa Samples. Human PCa samples were collected from 60 cases of surgically resected specimens of the pancreatic duct in Lianyungang Clinical College of Nanjing Medical University and Shanghai Oriental Clinical Medical School of Nanjing Medical University. All the samples had not received medical treatment and/or radiation treatment before surgery. The inclusion and exclusion criteria were according to a previous report [17]. Immediately after collection, the excised experimental specimens were immersed in an EP tube containing a preservation solution and stored in a −80°C refrigerator. All tissue samples used in the experiments were clearly diagnosed by two experienced pathologists. Signed written informed consent was obtained from the patients and/or guardians. This study was approved by the Ethics Committee of Lianyungang Clinical College of Nanjing Medical University.

2.2. Transfection. Lentivirus transfection was performed with sh-NC and sh-SLC35F2. Cells were collected for qPCR and western blotting analysis and cell function experiments. Cell transfection was performed according to the manufacturer’s protocol step by step.

2.3. CCK8 Assay. Cells (PCa cell lines: AsPC-1, PANC-1, MIA PaCa-2, CFPAC-1, BxPC-3, and normal pancreatic ductal epithelial cell line HPNE) were prepared for the Cell Counting Kit-8 (CCK-8) assay according to the manufacturer’s protocol.

2.4. Transwell Assay. Cell migration or invasion ability was measured using a 24-well plate cell according to instructions. Cells were then prepared into cell suspensions and seeded in the upper Transwell chamber (2.0 × 10^5 cells/well). The migrated cells were counted and observed after being stained by crystal violet.

2.5. RT-PCR. After culture for 48 h, total RNA was extracted from transfected cells using TRIzol reagent (Beyotime, Shanghai, China) and then reverse-transcribed using the PrimeScript RT reagent kit (KeyGen company, Nanjing, China). The protocols of RT-PCR were according to a previous report [17]. Each sample was tested in triplicate wells and repeated three times. The primer sequences are shown in Table 1. Expression data were normalized by β-actin levels by the 2−ΔΔCt method.

2.6. Western Blotting Assay. Transfected cells were collected after 72 h of culture, and proteins were extracted for quantitative detection with the total protein concentration determined using the BCA method. Immunoblotting was carried out using primary rabbit polyclonal anti-SLC35F2 (dilution: 1:500; Cat. no.: ab22854) and rabbit polyclonal anti-RBM14 (dilution: 1:500; Cat. no.: ab70636) with GAPDH (dilution: 1:500, Cat. no.: ab37168) as internal control, followed by incubation with the secondary goat anti-rabbit (HRP) IgG antibody (dilution: 1/2000; Cat. no.: ab6721). All the antibodies were purchased from Abcam (Cambridge, MA, USA). The semiquantitative analysis of the protein expressions was determined using alpha SP image software.

2.7. Luciferase Reporting Assay. PCa cells in good condition were used for luciferase assay. The relative fluorescence value was then detected by a photometer for comparison.

2.8. Statistical Analysis. SPSS 22.0 statistical software was used for data analyses. The relationship between SLC35F2 and clinicopathological characteristics was analyzed by χ² test. P < 0.05 was considered to be statistically significant.

3. Results

3.1. SLC35F2 Was Highly Expressed in PCa. qPCR detected SLC35F2 in 60 PCa samples and their adjacent tissues and PCa cell lines. Figures 1(a) and 1(b) show that tumor samples contained a significantly higher expression of SLC35F2 (Figures 1(a) and 1(b)). Meanwhile, SLC35F2 was markedly highly expressed in PCa cells (Figure 1(c)). Additionally, prognosis analysis revealed that high level of SLC35F2 indicated poor prognosis in patients with PCa (P < 0.05).

3.2. SLC35F2 Contributed to Cisplatin Resistance in PCa. Subsequently, qPCR and western blotting detected an increased expression of SLC35F2 in cisplatin-resistant PCa patients (Figure 2(a)). To further examine the impacts of SLC35F2 on the cisplatin resistance, SLC35F2 knockdown vectors were constructed in cisplatin-resistant PCa cells (Figure 2(b)). As a result, it was found that knockdown of SLC35F2 markedly attenuated the viability of the PCa cells (Figure 2(c)).

3.3. Knockdown of SLC35F2 Inhibited Cell Proliferation and Metastasis. Furthermore, to assess the influence of SLC35F2 on the proliferative ability of PCa cells, we constructed an
SLC35F2 knockdown model in PCa cisplatin-resistant cells (Figure 3(a)). Subsequently, results showed that inhibition of SLC35F2 significantly attenuated the proliferative rate and invasiveness (Figures 3(b) and 3(c)).

3.4. RBM14 Was Lowly Expressed in PCa. Bioinformatics research revealed that there may be some connection between SLC35F2 and RBM14 expression in PCa. Subsequently, SLC35F2 and RBM14 were cotransfected into PANC-1 and CFPAC-1 cell lines, and luciferase assay verified that SLC35F2 can directly bind to RBM14 (Figure 4(a)). In comparison with adjacent tissues, tumor tissue samples showed an increased expression of RBM14 (Figure 4(b)), which was positively correlated with RBM14 expression. Meanwhile, in cisplatin-resistant PCa cell lines PANC-1/DDP and CFPAC-1/DDP, knockdown of SLC35F2 remarkably reduced the protein expression of RBM14 (Figure 4(c)).

3.5. RBM14 Modulated SLC35F2 Expression. In order to investigate the association of SLC35F2 with RBM14, we overexpressed RBM14 in cisplatin-resistant PCa cell lines that silenced SLC35F2 and confirmed the transfection efficiency by western blotting (Figure 5(a)). Transwell assay

---

**Table 1: Primer sequence.**

| Gene   | Primer sequence |
|--------|-----------------|
| SLC35F2 | 5'-ATCCAGTGCTGCTGTGGTGA-3'  |
|        | 5'-TGCTTTGGAATGTAAGGAAG-3'  |
| RBM14  | 5'-TCTCGGGGTGATCGACAAG-3'  |
|        | 5'-CCCTTTGTTCATCTGCTGCTCCT-3'  |
| β-Actin| 5'-CCTGGCAAGCCAGCACAAT-3'  |
|        | 5'-GCTGATCCACATCTGCTGAA-3'  |

---

**Figure 1:** SLC35F2 is highly expressed in pancreatic cancer tissues and cell lines. (a, b) qRT-PCR detection of SLC35F2 expression in pancreatic cancer tumor tissue and nontumor tissue adjacent to the tumor; (c) qRT-PCR detection of SLC35F2 expression level in pancreatic cancer cell lines; Data are mean ± SD, *P < 0.05, **P < 0.01, and ***P < 0.001.
Figure 2: SLC35F2 increases the cisplatin resistance of pancreatic cancer cells. (a) qRT-PCR and western blotting detected SLC35F2 expression in cisplatin-resistant pancreatic cancer patients; (b) qRT-PCR and western blotting detected the expression level of SLC35F2 in pancreatic cancer cell lines PANC-1 and CFPAC-1 after transfection of the SLC35F2 knockdown vector; (c) CCK-8 cell proliferation experiments detected cell viability after transfection of SLC35F2 knockdown vector in pancreatic cancer cell lines PANC-1 and CFPAC-1. Data are mean ± SD, *P < 0.05, **P < 0.01.
Figure 3: Silencing SLC35F2 inhibited pancreatic cancer cell proliferation and metastasis. (a) qRT-PCR and western blotting verified the interference efficiency after transfection of SLC35F2 knockdown vectors in pancreatic cancer cisplatin-resistant PANC-1/DDP and CFPAC-1/DDP cell lines; (b) CCK-8 assay detected the proliferation rate of pancreatic cancer cells after transfection of the SLC35F2 knockdown vector in PANC-1/DDP and CFPAC-1/DDP cell lines; (c) Transwell invasion assay detected the invasion of pancreatic cancer cells after transfection of the SLC35F2 knockdown vector in PANC-1/DDP and CFPAC-1/DDP cell lines. Data are mean ± SD, *P < 0.05.
Figure 4: SLC35F2 can target RBM14. (a) Dual-luciferase reporter gene was used to verify the direct targeting of SLC35F2 to RBM14; (b) qRT-PCR detection of RBM14 expression differences in pancreatic cancer tumor tissue and adjacent tissues; (c) qRT-PCR and western blotting verified the expression level of RBM14 after downregulation of SLC35F2 in pancreatic cancer cisplatin-resistant PANC-1/DDP and CFPAC-1/DDP cell lines. Data are mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001.
demonstrated that overexpression of RBM14 reversed the effects of SLC35F2 downregulation on the invasive ability of PCa cells (Figure 5(b)).

4. Discussion

Currently, it is estimated that PCa will develop into the second leading cause of cancer-related mortality by 2020 [1–4]. Due to the lack of accurate early diagnosis methods and effective preventive measures, this cancer is usually diagnosed at advanced stages and shows a very poor response to chemotherapy drugs (including cisplatin) [6–8]. Recently, a variety of roles of SLC35F2 in cancers have been reported in different kinds of tumors [18–20]. Chen et al. demonstrated that SLC35F2 can promote malignant progression and is a potential therapeutic target in bladder cancer [18]. Li et al. showed that RNA interference-mediated downregulation of SLC35F2 expression by lentiviral vector can attenuate the proliferation, migration, and invasion of lung cancer cells [19]. Bu et al. found that highly expressed SLC35F2 was associated with non-small-cell lung cancer pathological staging and thus might be able to predict the prognosis of patients with NSCLC [20]. However, little evidence is available regarding the role of SLC35F2 in PCa.

In this study, we detected the SLC35F2 expression in 60 pairs of PCa patients’ tumor tissues and adjacent tissues and found that it was remarkably upregulated in tumors and positively related to poor prognosis, indicating that SLC35F2...
might be a cancer-promoting gene in PCa. In addition, to further understand the function of SLC35F2 in the formation and development of PCa, we knocked down SLC35F2 expression and found that downregulation of SLC35F2 increased the sensitivity of PCa to cisplatin and thus inhibited the proliferation and metastasis of PCa cells, indicating that SLC35F2 may inhibit the cisplatin sensitivity of PCa cells.

Bioinformatics analysis suggested that SLC35F2 could regulate RBM14 and thus affect cisplatin sensitivity, proliferation, and migration ability of PCa cells. We then confirmed the binding relationship and the positive regulation between SLC35F2 and RBM14 by a luciferase reporter gene assay and western blot. We subsequently found that overexpression of RBM14 significantly reversed the inhibitory effects of silencing SLC35F2 on PCa cell invasion, suggesting that SLC35F2 may regulate cisplatin resistance of PCa cells by modulating RBM14. Further understanding of the biological effects of SLC35F2 and RBM14 genes and their role in the development of tumors will be more helpful for the diagnosis, treatment, and prognosis evaluation of tumors.

5. Conclusion

In summary, SLC35F2 was remarkably upregulated in PCa, which was relevant to worse prognosis. Additionally, SLC35F2 may regulate cisplatin resistance of PCa cells and promote the malignancy of PCa via regulating RBM14.

Data Availability

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare that they have no conflicts of interest in this work.

Acknowledgments

This work was supported by Lianyungang High-Tech Zone Science and Technology Project (ZD201929).

References

[1] Q. J. Lin, F. Yang, C. Jin, and D. L. Fu, "Current status and progress of pancreatic cancer in China," World Journal of Gastroenterology, vol. 21, no. 26, pp. 7988–8003, 2015.
[2] M. Ilic and I. Ilic, "Epidemiology of pancreatic cancer," World Journal of Gastroenterology, vol. 22, no. 44, pp. 9694–9705, 2016.
[3] B. M. Wolpin, "Pancreatic cancer," Hematology-Oncology Clinics of North America, vol. 29, no. 4, 2015.
[4] D. Ansari, B. Tingstedt, B. Andersson et al., "Pancreatic cancer: yesterday, today and tomorrow," Future Oncology, vol. 12, no. 16, pp. 1929–1946, 2016.
[5] M. Brancaccio, F. Natale, G. Falco, and T. Angrisano, "Cell-free DNA methylation: the new frontiers of pancreatic cancer biomarkers’ discovery," Genes, vol. 11, no. 1, p. 14, 2019.
[6] G. Aleixo, S. Shachar, K. A. Nyrop, H. B. Muss, L. Malpica, and G. R. Williams, "Myoestosis and prognosis in cancer: systematic review and meta-analysis," Critical Reviews in Oncology, vol. 145, Article ID 102839, 2020.
[7] C. M. Grapa, T. Mocan, D. Gonciar et al., "Epidermal growth factor receptor and its role in pancreatic cancer treatment mediated by nanoparticles," International Journal of Nanomedicine, vol. 14, pp. 9693–9706, 2019.
[8] D. R. Freyer, P. Brock, K. Knight et al., "Interventions for cisplatin-induced hearing loss in children and adolescents with cancer," The Lancet Child and Adolescent Health, vol. 3, no. 8, pp. 578–584, 2019.
[9] Y. Zhao, X. Zou, G. Wang et al., "Effects of GATA6-AS/MMP9 on malignant progression of endometrial carcinoma," Journal of the Balkan Union of Oncology, vol. 26, no. 5, pp. 1789–1795, 2021.
[10] D. M. Tanase, E. M. Gosav, S. Radu et al., "The predictive role of the biomarker kidney molecule-1 (KIM-1) in acute kidney injury (AKI) cisplatin-induced nephotoxicity," International Journal of Molecular Sciences, vol. 20, no. 20, p. 5238, 2019.
[11] V. F. Vasconcellos, G. N. Marta, E. M. da Silva, A. F. Gois, T. B. de Castria, and R. Riera, "Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer," Cochrane Database of Systematic Reviews, vol. 1, Article ID D9256, 2020.
[12] J. K. Liao, B. Zhou, X. M. Zhuang, P. L. Zhuang, D. M. Zhang, and W. L. Chen, "Cancer-associated fibroblasts confer cisplatin resistance of tongue cancer via autophagy activation," Biomedicine and Pharmacotherapy, vol. 97, pp. 1341–1348, 2018.
[13] M. M. Silva, C. R. R. Rocha, G. S. Kinker, A. L. Pelegrini, and C. F. M. Menck, "The balance between NRF2/GSH antioxidant mediated pathway and DNA repair modulates cisplatin resistance in lung cancer cells," Scientific Reports, vol. 9, no. 1, Article ID 17639, 2019.
[14] S. H. Chen and J. Y. Chang, "New insights into mechanisms of cisplatin resistance: from tumor cell to microenvironment," International Journal of Molecular Sciences, vol. 20, no. 17, p. 4136, 2019.
[15] M. D. Nyquist, B. Prasad, and E. A. Mostaghel, "Harnessing solute carrier transporters for precision oncology," Molecules, vol. 22, no. 4, p. 539, 2017.
[16] M. A. Cousin, M. J. Smith, A. N. Sigafoos et al., "Utility of DNA, RNA, protein, and functional approaches to solve cryptic immunodeficiencies," Journal of Clinical Immunology, vol. 38, no. 3, pp. 307–319, 2018.
[17] Y. S. Ma, X. L. Yang, Y. S. Liu et al., "Long non-coding RNA NORAD promotes pancreatic cancer stem cell proliferation and self-renewal by blocking microRNA-202-5p-mediated ANP32E inhibition," Journal of Translational Medicine, vol. 19, no. 1, p. 400, 2021.
[18] M. Chen, X. Gao, D. Huang et al., "Knockdown of SLC35F2 inhibits the proliferation and metastasis of bladder cancer cells," OncoTargets and Therapy, vol. 12, pp. 10771–10786, 2019.
[19] X. Li, J. Li, G. Jiang et al., "Influence on the behavior of lung cancer H1299 cells by silencing SLC35F2 expression," Cancer Cell International, vol. 13, no. 1, p. 73, 2013.
[20] L. Bu, G. Jiang, F. Yang, J. Liu, and J. Wang, "Highly expressed SLC35F2 in non-small cell lung cancer is associated with pathological staging," Molecular Medicine Reports, vol. 4, no. 6, pp. 1289–1293, 2011.